Core Insights - The long-term follow-up results of the CAR-T cell product Zevor-cel (赛恺泽®) for treating relapsed/refractory multiple myeloma were presented at the 22nd International Myeloma Society (IMS) annual meeting [1] - Zevor-cel is an autologous CAR-T cell therapy targeting BCMA, approved by the National Medical Products Administration (NMPA) in China for adult patients with relapsed or refractory multiple myeloma who have undergone at least three lines of treatment [1] - The product received FDA's Regenerative Medicine Advanced Therapy (RMAT) designation and orphan drug status in 2019, indicating its potential significance in treating rare diseases [1] Company Overview - 科济药业-B (02171) is focused on developing innovative therapies for hematological malignancies, with Zevor-cel being a key product in its pipeline [1] - The company aims to address unmet medical needs in the treatment of multiple myeloma, a challenging condition with limited effective therapies available [1] Clinical Development - The Phase I clinical trial results of Zevor-cel were updated and showcased at the IMS annual meeting, highlighting the ongoing commitment to research and development in the field of CAR-T therapies [1] - The long-term follow-up data is crucial for understanding the efficacy and safety profile of Zevor-cel in a real-world patient population [1]
科济药业-B(02171)于2025年第22届IMS年会上呈列的赛恺泽的研究成果更新